Bringing Clarity to Clinical Decisions
Early detection remains essential to improving outcomes for bladder cancer patients.
Peter Black, MD, FACS
Professor and Vice Chair, Department of Urologic Sciences, Khosrowshahi Family Chair, University of British Columbia Senior Research Scientist, Vancouver Prostate Centre, Associate Director of Clinical Research, Vancouver Prostate Centre Urologic Oncologist, Vancouver General Hospital
Peter Black, MD, FACS, FRCSC
Scientific Advisory Board, Vesica Health
Dr. Black is a leading expert in bladder cancer, an active clinical trialist, and serves on the SWOG GU committee and as surgical co-chair of the NCI (US) Bladder Cancer Task Force. He previously served on the Board of Directors for the Societe Internationale d’Urologie (2013-2019) and is now the Vice President of the International Bladder Cancer Network.  He is Vice President of Education in the Canadian Urology Association (CUA) and Chair of the Medical Advisory Board of Bladder Cancer Canada. Dr. Black is also a member of the American Urological Association (AUA), European Association of Urologists (EAU), International Bladder Cancer Network (IBCN), and International Bladder Cancer Group (IBCG).
Dr. Black’s clinical subspecialty interest is in the treatment of urologic cancers, especially bladder and prostate cancer. He maintains a grant-funded translational research program in urothelial carcinoma with a focus on genomic analysis of response to chemotherapy, mechanisms of resistance to chemotherapy, and novel targeted therapies for bladder cancer.
